The Effect of Telmisartan on Collagen Percentages by Picrosirius Staining in the Glomerular Renal Organ of 8% NaCl-Induced Rats

Khairil Pahmi, M Sidratullah, M Ricky Ramadhian


Excessive salt consumption is one of the hypertension and kidney disease factors, while telmisartan is one of antihypertensive drugs used in the therapy. Telmisartan not only blocks angiotensin receptor which leads to the decrease of blood pressure, but also activates peroxisome proliferator activated receptor gamma (PPAR-γ) and inhibits transforming growth expression factor of beta-1 (TGFβ-1). Whether telmisartan decreases the kidney collagen volume fraction of excessive NaCl-induced Wistar rats are studied in this experiment. Twenty five male Wistars 2.5-3 months of age and 100-150 g BW rats were used in this research. They were grouped into 5, each consists of 5 rats. Group I (G I) as first negative control did not receive NaCl and telmisartan. G II as second negative control received NaCl but not telmisartan. G III, IV and V received NaCl and telmisartan 3, 6 and 12 mg/kg BW. The treatments were given every day within 8 weeks. At the day of 56 all rats were sacrificed by mean of neck dislocation and operated to take the kidney. The collagen was stained by picrosirius red staining. Data were expressed as mean ± standard deviation. They were analyzed by parametric test (analysis of variance-ANOVA and paired samples t-test) or nonparametric test (Kruskal-Wallis). A value of p<0.05 was considered statistically significant. The results showed that intraglomerular and extraglomerular collagen volume fraction were lower in telmisartan-treated Wistar rats group than negative control group (0.05<p<0.05). In conclusion, intraglomerular and extraglomerular collagen volume fraction were lower in 8% sodium chloride-induced and telmisartan-treated male Wistar rats than the items of negative control group.


NaCl, Telmisartan, TGF-β, Collagen

Full Text:



World Health Organisation (WHO) (2010) Global status report on non-communicable diseases. Geneva, Switzerland.

Baltatzi M, Ch S, Hatzitolios A (2011) Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Hippokratia 15: 2732.

Blaustein MP, Leenen FHH, Chen L, Golovina VA, Hamlyn JM, et al. (2012) How NaCl raises blood pressure: A new paradigm for the pathogenesis of saltdependent hypertension. Am J Physiol Heart Circ Physiol 302: H1031-H1049.

Cox N, Pilling D, Gomer RH (2012) NaCl potentiates human fibrocyte differentiation. PLoS One 7: 1-9.

Beevers G, Lip GYH, O’Brien E (2001) ABC of hypertension: “The pathophysiology of hypertension”. BMJ 322: 912-916.

He FJ, Jenner KH, MacGregor GA, Avenue G (2012) Telmisartan exerts renoprotective actions via peroxisome. Hypertension 59: 308-316.

Meneton P, Jeunemaitre X, Wardener HEDE, Macgregor GA (2005) Links between dietary salt intake, renal salt handling, blood pressure and cardiovascular diseases. Physiol Rev 86: 679-715.

Yu HCM, Burrell LM, Black MJ, Wu LL, Dilley RJ (1998) Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98: 2621-2628.

Leenen FHH (2010) The central role of the brain aldosterone – “ouabain” pathway in salt-sensitive hypertension. BBA Mol Basis Dis 1802: 1132-1139.

Jöhren O, Dendorfer A, Dominiak P (2004) Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 62: 460-467.

Starr C, McMillan B (2012) Human Biology. 9th Edn. Brooks/Cole Cengage Learning, Canada.

Mezzano SA, Ruiz-Ortega M, Egido J (2001) Angiotensin II and renal fibrosis. Hypertension 38: 635638.

Chambers S, Schachter M, Morrell J, Gaw A, Kirby M (2008) Telmisartan an effective anti-hypertensive for 24 h blood pressure control. Drugs in Context 4: 1-14.

Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J (2009) Telmisartan as a peroxisome proliferatoractivated receptor - Á ligand is a new target in the treatment of human renal cell carcinoma. Mol Med Rep 2: 193-198.

Rotman N, Wahli W (2010) PPAR modulation of kinase-linked receptor signaling in physiology and disease. Physiology 25: 176-185.

Xu L, Liu Y (2013) Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats. Physiol Res 62: 351-359.

Younis F, Stern N, Limor R, Oron Y, Zangen S (2010) Telmisartan ameliorates hyperglycemia and metabolic profile in non-obese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-γ activation. Metabolism 59: 1200-1209.

Matsumura T, Kinoshita H, Ishii N, Fukuda K, Motoshima H (2011) Telmisartan exerts antiatherosclerotic effects by activating in macrophages. Arterioscler Thromb Vasc Biol 31: 1268-1275.

Liu W, Wang W, Song SW, Gu XF, Ma XJ (2011) Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats. J Cardiovasc Pharmacol 57: 308-316.

Jawi IM, Yasa IWPS, Suprapta DN, Mahendra AN (2012) Anti-hypertensive effect and eNOS expressions in NaCl-induced hypertensive rats treated with purple sweet potato. Univ J Med Dent 1: 102-107.

Lync MJ, Raphael SS, Mellor LD, Spare PD, Inwood MJH, et al. (1969) Medical Laboratory Technology and Clinical Pathology. W.B. Saunders Company, United States of America (USA).

Fatchiyah AEL, Widyarti S, Rahayu S (2011) Biologi Molekuler "Prinsip Dasar Analisis". Erlangga, Jakarta. 23. Shang QH, Min XQ, Liu C, Mao WH, Shang QH (2012) Effects of high salt diet on arterial remodelling and the intervention of telmisartan in wistar rats. Heart 98: E1-E319.



  • There are currently no refbacks.

Copyright (c) 2020 Journal Syifa Sciences and Clinical Research

  Department of Pharmacy, Gorontalo State University
Jl. Jenderal Sudirman No.6, Kota Gorontalo, Provinsi Gorontalo 96128, Indonesia

Creative Commons License

Journal Syifa Sciences and Clinical Research (JSSCR) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.